147 related articles for article (PubMed ID: 12782127)
1. Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product.
Ianzano L; Zhao XC; Minassian BA; Scherer SW
Genomics; 2003 Jun; 81(6):579-87. PubMed ID: 12782127
[TBL] [Abstract][Full Text] [Related]
2. The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain.
Ganesh S; Tsurutani N; Suzuki T; Ueda K; Agarwala KL; Osada H; Delgado-Escueta AV; Yamakawa K
Hum Mol Genet; 2003 Sep; 12(18):2359-68. PubMed ID: 12915448
[TBL] [Abstract][Full Text] [Related]
3. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.
Ganesh S; Agarwala KL; Ueda K; Akagi T; Shoda K; Usui T; Hashikawa T; Osada H; Delgado-Escueta AV; Yamakawa K
Hum Mol Genet; 2000 Sep; 9(15):2251-61. PubMed ID: 11001928
[TBL] [Abstract][Full Text] [Related]
4. Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin.
Singh S; Satishchandra P; Shankar SK; Ganesh S
Hum Mutat; 2008 Jun; 29(6):E1-12. PubMed ID: 18311786
[TBL] [Abstract][Full Text] [Related]
5. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy.
Minassian BA; Ianzano L; Meloche M; Andermann E; Rouleau GA; Delgado-Escueta AV; Scherer SW
Neurology; 2000 Aug; 55(3):341-6. PubMed ID: 10932264
[TBL] [Abstract][Full Text] [Related]
6. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.
Fernández-Sánchez ME; Criado-García O; Heath KE; García-Fojeda B; Medraño-Fernández I; Gomez-Garre P; Sanz P; Serratosa JM; Rodríguez de Córdoba S
Hum Mol Genet; 2003 Dec; 12(23):3161-71. PubMed ID: 14532330
[TBL] [Abstract][Full Text] [Related]
7. Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
Gómez-Garre P; Sanz Y; Rodríguez De Córdoba SR; Serratosa JM
Eur J Hum Genet; 2000 Dec; 8(12):946-54. PubMed ID: 11175283
[TBL] [Abstract][Full Text] [Related]
8. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.
Chan EM; Ackerley CA; Lohi H; Ianzano L; Cortez MA; Shannon P; Scherer SW; Minassian BA
Hum Mol Genet; 2004 Jun; 13(11):1117-29. PubMed ID: 15102711
[TBL] [Abstract][Full Text] [Related]
9. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy.
Dubey D; Ganesh S
Hum Mol Genet; 2008 Oct; 17(19):3010-20. PubMed ID: 18617530
[TBL] [Abstract][Full Text] [Related]
10. Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy.
Ianzano L; Young EJ; Zhao XC; Chan EM; Rodriguez MT; Torrado MV; Scherer SW; Minassian BA
Hum Mutat; 2004 Feb; 23(2):170-176. PubMed ID: 14722920
[TBL] [Abstract][Full Text] [Related]
11. Early-onset Lafora body disease.
Turnbull J; Girard JM; Lohi H; Chan EM; Wang P; Tiberia E; Omer S; Ahmed M; Bennett C; Chakrabarty A; Tyagi A; Liu Y; Pencea N; Zhao X; Scherer SW; Ackerley CA; Minassian BA
Brain; 2012 Sep; 135(Pt 9):2684-98. PubMed ID: 22961547
[TBL] [Abstract][Full Text] [Related]
12. Relationship between glycogen accumulation and the laforin dual specificity phosphatase.
Wang W; Parker GE; Skurat AV; Raben N; DePaoli-Roach AA; Roach PJ
Biochem Biophys Res Commun; 2006 Nov; 350(3):588-92. PubMed ID: 17022935
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy.
Dubey D; Parihar R; Ganesh S
Genomics; 2012 Jan; 99(1):36-43. PubMed ID: 22036712
[TBL] [Abstract][Full Text] [Related]
14. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
Couarch P; Vernia S; Gourfinkel-An I; Lesca G; Gataullina S; Fedirko E; Trouillard O; Depienne C; Dulac O; Steschenko D; Leguern E; Sanz P; Baulac S
J Mol Med (Berl); 2011 Sep; 89(9):915-25. PubMed ID: 21505799
[TBL] [Abstract][Full Text] [Related]
15. Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.
Spuch C; Ortolano S; Navarro C
Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):99-107. PubMed ID: 22369717
[TBL] [Abstract][Full Text] [Related]
16. Identification of new and common mutations in the EPM2A gene in Lafora disease.
Minassian BA; Ianzano L; Delgado-Escueta AV; Scherer SW
Neurology; 2000 Jan; 54(2):488-90. PubMed ID: 10668720
[TBL] [Abstract][Full Text] [Related]
17. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Gentry MS; Worby CA; Dixon JE
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8501-6. PubMed ID: 15930137
[TBL] [Abstract][Full Text] [Related]
18. Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes.
Ianzano L; Zhang J; Chan EM; Zhao XC; Lohi H; Scherer SW; Minassian BA
Hum Mutat; 2005 Oct; 26(4):397. PubMed ID: 16134145
[TBL] [Abstract][Full Text] [Related]
19. Advances in lafora progressive myoclonus epilepsy.
Delgado-Escueta AV
Curr Neurol Neurosci Rep; 2007 Sep; 7(5):428-33. PubMed ID: 17764634
[TBL] [Abstract][Full Text] [Related]
20. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
